Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 4/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | CCR9 | P51686 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20899691 | 1.00 | MEN1 (0.44) | MEN1CYP1A2KMT2AEPHX2KIF11 | |
| SCHEMBL20899804 | 0.84 | CYP1A2 (0.44) | MEN1CYP1A2KMT2ACA1CA2 | |
| SCHEMBL20899803 | 0.84 | CYP1A2 (0.44) | MEN1CYP1A2KMT2ACA1CA2 | |
| SCHEMBL7412854 | 0.84 | MEN1 (0.63) | MEN1CYP1A2KMT2AEPHX2KIF11 | |
| SCHEMBL28889780 | 0.80 | EPHX2 (0.38) | MEN1KMT2AEPHX2KIF11MMP2 | |
| SCHEMBL21112534 | 0.80 | CYP1A2 (0.49) | MEN1CYP1A2KMT2AEPHX2 | |
| SCHEMBL21112536 | 0.80 | CYP1A2 (0.49) | MEN1CYP1A2KMT2AEPHX2 | |
| SCHEMBL21112387 | 0.80 | CYP1A2 (0.40) | MEN1CYP1A2KMT2A | |
| SCHEMBL20899692 | 0.79 | CYP1A2 (0.47) | MEN1CYP1A2KMT2AKIF11CA1 | |
| SCHEMBL20899802 | 0.79 | MEN1 (0.47) | MEN1CYP1A2KMT2AEPHX2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694846-B1 | 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS | GILEAD SCIENCES INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| EP-3694846-A1 | 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS | Gilead Sciences, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| WO-2019075291-A1 | 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, FURIN | MEN1 2814/4885CYP1A2 2161/4885KMT2A 1556/4885 |
| US-10774053-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | MEN1 2814/4885CYP1A2 2161/4885KMT2A 1556/4885 |
| US-11352329-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | MEN1 2814/4885CYP1A2 2161/4885KMT2A 1556/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | MEN1 463/4885CYP1A2 2655/4885KMT2A 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.